血浆elisa检测及中和活性。a-b,感染12个月后(N=63),血浆IgG抗体结合SARS-CoV-2 RBD (a)和N蛋白(b),血浆中和活性(c-e)。a和b,分别为未接种疫苗者(黑线)和接受一剂或两剂COVID-19 mRNA疫苗者(蓝线)的ELISA曲线(左图)。曲线下面积(AUC)随时间在未接种和接种个体中显示(中间的面板)。样本采集前24-48小时接受第一剂疫苗的两名患者用紫色表示。线连接纵向样品。红色的数字表示指定时间点的几何平均AUC。最右边的面板显示组合值作为一个点图为所有个人。c,将平均NT50分别按1.3个月(浅灰色)和6.2个月(深灰色)、12个月(橙色)对未接种个体和接受一剂或两剂COVID-19 mRNA疫苗的个体进行排名。样本采集前24-48小时接受第一剂疫苗的两名患者用紫色表示。 d, e, NT50 over time in non-vaccinated (d) and vaccinated individuals (e). Lines connect longitudinal samples from the same individual. Two individuals who received their first dose of vaccine 24-48 hours before sample collection are depicted in purple. Red numbers indicate the geometric mean NT50 at the indicated timepoint. Statistical significance in a, b, d and e was determined using Friedman Multiple Comparisons test. f, Plasma neutralizing activity against SARS-CoV-2 variants of concern. All experiments were performed at least in duplicate.
用户评论